Ashvattha Therapeutics, Inc
Tuesday, February 27, 2024
Plymouth
Ophthalmology
Ashvattha is a clinical stage company with a transformative nanomedicine technology exclusively licensed from Johns Hopkins University. The nanomedicine, hydroxyl dendrimers (HDs), precisely targets reactive inflammatory cells anywhere in the body. HD therapeutics (HDTs) are a new drug class that targets diseased tissue and are renally excreted intact in humans without observed toxicity. We have clinical programs in ophthalmology, neurology, and inflammation:
1) Phase 2 chronic dosing study of subcutaneous, anti-angiogenic D-4517.2 in wet AMD and DME patients is ongoing. Results expected 1H24.
2) Phase 1/2 study to image neuroinflammation in ALS, MS, PD and AD patients with 18F-OP-801 is ongoing. Results expected 1H24. Imaging results to support HDT development program.
State
CA
Country
United States
Website
http://www.avttx.com
CEO/Top Company Official
Jeffrey L Cleland, PhD
Lead Product in Development
D-4517.2 (hydroxyl dendrimer VEGFR tyrosine kinase inhibitor) is a potent, subcutaneously administered anti-angiogenic nanomedicine that crosses the blood-retinal barrier and selectively targets activated microglia, macrophages, and hypertrophic retinal pigment epithelial cells in the eye. D-4517.2 has the potential to change the current treatment paradigm for neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME) by extending the time between intravitreal anti-VEGF injections via a subcutaneous injection self-administered by the patient. Furthermore, subcutaneous administration of D-4517.2 has the potential to treat both eyes at the same time, a significant benefit for 40-50% of patients with bilateral disease. D-4517.2 is in a Phase 2 chronic dosing clinical trial in subjects with wet AMD or DME.
Development Phase of Primary Product
Phase II
Number Of Unlicensed Products
Products are available to license with exception of China (China rights to D-4517.2, OP-801 and OP-101 held by Huadong Medicine)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
)
)
){kind=logo}